Jaguar Health (JAGX) Stock Forecast and Price Target (2026)

Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with JAGX. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.

Figures are approximate, tied to the asOf date, and distorted by one-time items and two 2026 reverse splits, so standard valuation multiples are not meaningful here; per-share figures cannot be compared across splits. The market values Jaguar at roughly ~$7 million, which reflects ~$3.8 million of cash, ~$16.7 million of debt and an ongoing loss rate far larger than either. The balance sheet, the timing of any Future Pak milestones and the terms of the new Series R preferred matter far more than reported earnings; verify live data before acting.

No analyst publishes estimates on JAGX, so these are the most recent figures we hold, as of October 2026. They describe where the company stands, not where it is going.

• Revenue (TTM): ~$27.8 million, mostly the one-time ~$19 million Q1 license fee; June-quarter revenue down ~59% y/y
• Recurring product revenue (Q1 2026): ~$1.2 million for prescription products (Mytesi, Gelclair, Canalevia-CA1)
• Net income (TTM): ~-$52.4 million, despite a Q1 2026 profit of ~$8.7 million from the license fee
• Cash / debt (June 30, 2026): ~$3.8 million / ~$16.7 million
• Market capitalization: ~$7.4 million at ~$3.79 per share (October 16, 2026)
• Share price change (split-adjusted): ~-99.3% year to date, ~-99.7% over one year
• Share history: Multiple reverse splits, including 1-for-35 on April 30, 2026 and another on September 17, 2026; special Series R preferred stock dividend in October 2026

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering JAGX do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Jaguar Health can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are Future Pak license and non-dilutive cash, Crofelemer rare-disease pipeline, A simpler, more focused business. The risk cited most often against it is the dominant risks are financing and dilution.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the JAGX is it a buy page. This page deliberately stops at the numbers.